Announcements
The new Eurosurveillance website is almost here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc


In this issue


Home Eurosurveillance Edition  2011: Volume 16/ Issue 7 Article 5
Back to Table of Contents
Previous Download (pdf)
Next

Eurosurveillance, Volume 16, Issue 7, 17 February 2011
News
European Parliament adopts resolution on the Tuberculosis Vaccine Initiative (TBVI)
  1. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

Citation style for this article: Eurosurveillance editorial team. European Parliament adopts resolution on the Tuberculosis Vaccine Initiative (TBVI). Euro Surveill. 2011;16(7):pii=19795. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19795

On 3 February 2011 the European Parliament adopted a resolution which highlights the role that the European Union (EU) can play in meeting the Millennium Development Goal (MDG) to halt and begin to reverse the incidence of tuberculosis (TB) by 2015. While progress has been made, the disease still causes almost 2 million deaths every year, with mortality especially high in developing countries and among sufferers of HIV/AIDS [1,2].

But TB is still a danger to European citizens as well, because of the worrying emergence of strains of tuberculosis resistant or highly resistant to treatment. In addition, the cost of TB treatment alone in the EU is EUR 2 billion per year [3].

According to the European Parliament, only a vaccination programme involving a large-scale vaccination campaign could have a positive impact in achieving the MDG to reduce prevalence and death rates after 2015, and in particular the elimination of TB by 2050.

MEPs highlight the central role that can be played by Tuberculosis Vaccine Initiative (TBVI), an independent, not-for-profit organisation that develops new vaccines, with the aim of making them globally accessible and affordable. According to the resolution, the TBVI's work should be included in the practical implementation of the Europe 2020 Strategy [4] and a much greater pharmaceutical research effort should be put in tackling diseases such as TB.


References

  1. European Parliament. European Parliament resolution of 3 February 2011 on the Tuberculosis Vaccine Initiative (TBVI) – practical implementation of the Europe 2020 strategy with a view to meeting MDG 6 and eliminating tuberculosis by 2050. 3 Feb 2011. Available from: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&reference=P7-TA-2011-0039&language=EN&ring=B7-2011-0089
  2. World Health Organization (WHO). The global plan to stop TB 2011-2015: transforming the fight towards elimination of tuberculosis. Geneva: WHO. 2010. Available from: http://www.stoptb.org/assets/documents/global/plan/TB_GlobalPlanToStopTB2011-2015.pdf
  3. European Lung Foundation. Tuberculosis. Burden in Europe. [Accessed 17 Feb 2011]. Available from: http://www.european-lung-foundation.org/index.php?id=77
  4. European Commission (EC). Europe 2020. A European strategy for smart, sustainable and inclusive growth. Brussels: EC. 3 Mar 2010. Available from: http://eunec.vlor.be/detail_bestanden/doc014%20Europe%202020.pdf


Back to Table of Contents
Previous Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.